ANTIMALARIAL-DRUGS, SYSTEMIC LUPUS-ERYTHEMATOSUS AND PREGNANCY
- 1 April 1988
- journal article
- research article
- Vol. 15 (4) , 607-610
Abstract
Antimalarial drugs containing the 4-amino quinoline radical are used to help control disease activity in discoid lupus erythematosus and systemic lupus erythematosus (SLE). Many patients with these complaints are yound women, some of whom will become pregnant. The use of these substituted 4-amino quinoline compounds in pregnancy is controversial. We studied the full obstetric histories of 8 women with SLE who had taken either chloroquine phosphate or hydroxychloroquine sulphate (Plaquenil) throughout the entire length of at least 1 pregnancy. These 8 women had 14 pregnancies while receiving antimalarial drugs. Fetal wastage was high in these patients, regardless of antimalarial therapy, and was almost 100% in patients who were clinically active. Six normal full term spontaneous deliveries resulted from these pregnancies with clinically healthy normal babies born despite exposure to antimalarial therapy throughout the pregnancies.This publication has 7 references indexed in Scilit:
- Antibody to Cardiolipin as a Predictor of Fetal Distress or Death in Pregnant Patients with Systemic Lupus ErythematosusNew England Journal of Medicine, 1985
- Safety of chloroquine in chemosuppression of malaria during pregnancy.BMJ, 1985
- FETAL SURVIVAL AFTER PREDNISONE SUPPRESSION OF MATERNAL LUPUS-ANTICOAGULANTThe Lancet, 1983
- SYSTEMIC LUPUS-ERYTHEMATOSUS AND PREGNANCY1980
- Systemic lupus erythematosus in pregnancyAmerican Journal of Obstetrics and Gynecology, 1979
- The Ototoxicity of Chloroquine PhosphateJAMA Otolaryngology–Head & Neck Surgery, 1964
- Relation of Positive L.E.-Cell Preparations to Activity of Lupus Erythematosus and Corticosteroid TherapyNew England Journal of Medicine, 1962